Ignite Creation Date:
2025-12-25 @ 12:03 AM
Ignite Modification Date:
2025-12-25 @ 10:01 PM
Study NCT ID:
NCT05170958
Status:
RECRUITING
Last Update Posted:
2025-05-22
First Post:
2021-11-17
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D007267', 'term': 'Injections'}], 'ancestors': [{'id': 'D004333', 'term': 'Drug Administration Routes'}, {'id': 'D004358', 'term': 'Drug Therapy'}, {'id': 'D013812', 'term': 'Therapeutics'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 396}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2022-01-06', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-05', 'completionDateStruct': {'date': '2026-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-05-21', 'studyFirstSubmitDate': '2021-11-17', 'studyFirstSubmitQcDate': '2021-12-09', 'lastUpdatePostDateStruct': {'date': '2025-05-22', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-12-28', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Maximum tolerated dose (MTD)', 'timeFrame': 'All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal （Visit 30 days after discontinuation of treatment or withdraw from the visit）', 'description': 'During the dose-escalation phase, the highest dose of dose-limiting toxicity for subjects less than or equal to 1/6 of the study drug within 3 weeks of starting treatment in Phase I study.'}, {'measure': 'Dose-limiting toxicities（DLT)', 'timeFrame': 'Within 3 weeks after receiving the first dose of the test drug', 'description': 'During the DLT observation period, the subject has an event that is reasonably related to the test drug (possibly, likely or definitely related) in Phase I study.'}, {'measure': 'Objective Response Rate (ORR)', 'timeFrame': 'All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal （Visit 30 days after discontinuation of treatment or withdraw from the visit）', 'description': 'Defined as the percentage of subjects having a Complete Response or Partial Response(ORR, including after immunotherapy complete response (iCR) and partial response (iPR)),will be determined by investigator assessment of radiographic disease assessments per RECIST V1.1. It was used to evaluate the efficacy of LBL-024 in Phase II study.'}], 'secondaryOutcomes': [{'measure': 'Adverse events and serious adverse events', 'timeFrame': 'All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal （Visit 30 days after discontinuation of treatment or withdraw from the visit）', 'description': 'Laboratory examination, physical examination, vital signs and electrocardiogram, etc.'}, {'measure': 'Maximum serum concentration (Cmax)', 'timeFrame': 'All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal （Visit 30 days after discontinuation of treatment or withdraw from the visit）', 'description': 'To determine the PK profile of LBL-024'}, {'measure': 'Immunogenicity', 'timeFrame': 'All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal （Visit 30 days after discontinuation of treatment or withdraw from the visit）', 'description': 'Incidence of subjects with anti-drug antibody (ADA) and neutralizing antibody (if applicable)'}, {'measure': 'Disease Control Rate(DCR)', 'timeFrame': 'Visit 30 days after discontinuation of treatment or withdraw from the visit', 'description': 'Defined as percentage of participants having CR, PR, iCR，iPR or SD as best on-study response'}, {'measure': 'Progression-free survival (PFS)', 'timeFrame': 'All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal（Visit 30 days after discontinuation of treatment or withdraw from the visit）', 'description': 'Defined as the time from random assignment in a clinical trial to disease progression or death from any cause, has recently become an endpoint of considerable interest in the study of new oncology drugs.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Advanced Solid Tumor']}, 'descriptionModule': {'briefSummary': 'To evaluate the phase I/II clinical study of LBL-024 in the treatment of patients with advanced malignant tumors', 'detailedDescription': 'This trial is a single-arm, open-label, phase I/II clinical study of LBL-024 in patients with advanced malignant tumors. The phase I dose escalation and PK expansion phase plans to include patients with advanced malignant tumors who have failed previous standard treatment or do not have standard treatment or are not applicable to standard treatment at this stage. The phase IIa indication expansion phase plans to include patients with advanced malignant tumors , and evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, immunogenicity and preliminary efficacy. Single-arm registry clinical study to be conducted in Phase IIb.\n\nThis trial includes two parts:\n\nPart I: A Phase I/IIa clinical study on the safety, tolerability, PK and efficacy of LBL-024 in patients with advanced malignant tumor.\n\nPart II:Phase IIb is a pivotal single-arm clinical study.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Agree to comply with the trial treatment plan and visit plan, voluntarily agree to sign the informed consent form;\n2. 18-75 years old (including boundary value), no gender limit in the I/IIa trial phase；18-80 years old (including boundary value), no gender limit in the IIb trial phase；\n3. Subject has adequate organ and bone marrow function，Conforming to laboratory test results:\n4. The expected survival time is at least 12 weeks\n5. ECOG score is 0-1\n6. Males with fertility and females of childbearing age are willing to take effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug (including abstinence, intrauterine device, various hormonal contraception, correct use of contraception Sets，etc）; Women of childbearing age include pre-menopausal women and women within 2 years after menopause. Women of childbearing age must have a negative pregnancy test within 7 days before the first trial drug is administered.\n\nExclusion Criteria:\n\n1. Receiving other unmarketed clinical research drugs or treatments within 4 weeks before using the research drug for the first time;\n2. Brain parenchymal metastases or meningeal metastases with clinical symptoms, which are not suitable for inclusion in the group by the investigator's judgment;\n3. medical history of immunodeficiency including positive HIV antibody test;\n4. Women who are pregnant or breastfeeding;\n5. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in the study"}, 'identificationModule': {'nctId': 'NCT05170958', 'briefTitle': 'A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors', 'organization': {'class': 'INDUSTRY', 'fullName': 'Nanjing Leads Biolabs Co.,Ltd'}, 'officialTitle': 'A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of LBL-024 in Patients With Advanced Malignant Tumors', 'orgStudyIdInfo': {'id': 'LBL-024-CN001'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'LBL-024', 'description': 'LBL-024 injection; Initial dose - MTD; Q3W', 'interventionNames': ['Drug: LBL-024 for Injection']}], 'interventions': [{'name': 'LBL-024 for Injection', 'type': 'DRUG', 'otherNames': ['LBL-024'], 'description': 'LBL-024 was given every three weeks for treatment', 'armGroupLabels': ['LBL-024']}]}, 'contactsLocationsModule': {'locations': [{'zip': '230000', 'city': 'Hefei', 'state': 'Anhui', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'The First Affiliated Hospital of Anhui Medical University', 'geoPoint': {'lat': 31.86389, 'lon': 117.28083}}, {'zip': '230002', 'city': 'Hefei', 'state': 'Anhui', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Anhui Provincial Hospital', 'geoPoint': {'lat': 31.86389, 'lon': 117.28083}}, {'zip': '230601', 'city': 'Hefei', 'state': 'Anhui', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'The Second Hospital of Anhui Medical University', 'geoPoint': {'lat': 31.86389, 'lon': 117.28083}}, {'zip': '100005', 'city': 'Beijing', 'state': 'Beijing Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Peking Union Medical College Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '100021', 'city': 'Beijing', 'state': 'Beijing Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Cancer Hospital Chinese Academy of Medical Sciences', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '100142', 'city': 'Beijing', 'state': 'Beijing Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '025-83378099-848'}], 'facility': 'Beijing Cancer Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '400030', 'city': 'Chongqing', 'state': 'Chongqing Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'ji feng', 'role': 'CONTACT', 'email': 'fengji@leadsbiolabs.com', 'phone': '025-83378099'}], 'facility': 'Chongqing Cancer Hospital', 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}, {'zip': '350000', 'city': 'Fuzhou', 'state': 'Fujian', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '025-83378099'}], 'facility': 'Fujian Cancer Hospital', 'geoPoint': {'lat': 26.06139, 'lon': 119.30611}}, {'zip': '350000', 'city': 'Fuzhou', 'state': 'Fujian', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}, {'name': 'feng', 'role': 'CONTACT'}], 'facility': 'Fujian Medical University Union Hospital', 'geoPoint': {'lat': 26.06139, 'lon': 119.30611}}, {'zip': '361000', 'city': 'Xiamen', 'state': 'Fujian', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'The First Affiliated Hospital of Xiamen University', 'geoPoint': {'lat': 24.47979, 'lon': 118.08187}}, {'zip': '510062', 'city': 'Guangzhou', 'state': 'Guangdong', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'The First Affiliated Hospital,Sun Yat-sen University', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '510000', 'city': 'Guanzhou', 'state': 'Guangdong', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Sun Yat-sen University Cancer Center', 'geoPoint': {'lat': 23.06828, 'lon': 113.37117}}, {'zip': '530000', 'city': 'Nanning', 'state': 'Guangxi', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute', 'geoPoint': {'lat': 22.81667, 'lon': 108.31667}}, {'zip': '563000', 'city': 'Zunyi', 'state': 'Guizhou', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Affiliated Hospital of Zunyi Medical University', 'geoPoint': {'lat': 27.68667, 'lon': 106.90722}}, {'zip': '310000', 'city': 'Hangzhou', 'state': 'Hangzhou', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Sir Run Run Shaw Hospital', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '050011', 'city': 'Shijiazhuang', 'state': 'Hebei', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Fourth Hospital of Hebei Medical University', 'geoPoint': {'lat': 38.04139, 'lon': 114.47861}}, {'zip': '150000', 'city': 'Harbin', 'state': 'Heilongjiang', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Harbin Medical University Cancer Hospital', 'geoPoint': {'lat': 45.75, 'lon': 126.65}}, {'zip': '455000', 'city': 'Anyang', 'state': 'Henan', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Anyang Tumor Hospital', 'geoPoint': {'lat': 36.096, 'lon': 114.38278}}, {'zip': '471003', 'city': 'Luoyang', 'state': 'Henan', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '025-83378099'}], 'facility': 'The First Affilated Hospital of Henan University of Science & Technology', 'geoPoint': {'lat': 34.67345, 'lon': 112.43684}}, {'zip': '450000', 'city': 'Zhengzhou', 'state': 'Henan', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Henan Cancer Hospital', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'zip': '450052', 'city': 'Zhengzhou', 'state': 'Henan', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'The First Affiliated Hospital of Zhengzhou University', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'city': 'Zhengzhou', 'state': 'Henan', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'ji feng', 'role': 'CONTACT', 'email': 'fengji@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': "Henan Provincial People's Hospital", 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'zip': '430000', 'city': 'Wuhan', 'state': 'Hubei', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Tongji Hospital', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}, {'zip': '430000', 'city': 'Wuhan', 'state': 'Hubei', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Wuhan Union Hospital of China', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}, {'zip': '430079', 'city': 'Wuhan', 'state': 'Hubei', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu O ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Hubei Cancer Hospital', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}, {'zip': '441000', 'city': 'Xiangyang', 'state': 'Hubei', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Xiangyang Central Hospital', 'geoPoint': {'lat': 32.0422, 'lon': 112.14479}}, {'zip': '410031', 'city': 'Changsha', 'state': 'Hunan', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Hunan Cancer Hospital', 'geoPoint': {'lat': 28.19874, 'lon': 112.97087}}, {'zip': '210000', 'city': 'Nanjing', 'state': 'Jiangsu', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Jiangsu Cancer Hospital', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'zip': '210000', 'city': 'Nanjing', 'state': 'Jiangsu', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Nanjing First Hospital', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'zip': '210008', 'city': 'Nanjing', 'state': 'Jiangsu', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu Ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '025-83378099-848'}], 'facility': 'Nanjing Drum Tower Hospital', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'zip': '330000', 'city': 'Nanchang', 'state': 'Jiangxi', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'The Second Affiliated Hospital Nanchang University', 'geoPoint': {'lat': 28.68396, 'lon': 115.85306}}, {'zip': '330006', 'city': 'Nanchang', 'state': 'Jiangxi', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'The Ferst Affiliated Hospital of Nanchang University', 'geoPoint': {'lat': 28.68396, 'lon': 115.85306}}, {'zip': '130000', 'city': 'Ch’ang-ch’un', 'state': 'Jilin', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'The First Hospital of Jilin University', 'geoPoint': {'lat': 42.74694, 'lon': 126.24667}}, {'zip': '110000', 'city': 'Shenyang', 'state': 'Liaoning', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Liaoning Cancer Hospital & Institute', 'geoPoint': {'lat': 41.79222, 'lon': 123.43278}}, {'zip': '110000', 'city': 'Shenyang', 'state': 'Liaoning', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'The First Hospital of China Medical University', 'geoPoint': {'lat': 41.79222, 'lon': 123.43278}}, {'zip': '250000', 'city': 'Jinan', 'state': 'Shandong', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Qilu Hospital of Shandong University', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}}, {'zip': '250000', 'city': 'Jinan', 'state': 'Shandong', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Shandong Cancer Hospital & Institute', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}}, {'zip': '200032', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Fudan University Shanghai Cancer Center', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '030000', 'city': 'Taiyuan', 'state': 'Shanxi', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Shanxi Bethune Hospital', 'geoPoint': {'lat': 37.86944, 'lon': 112.56028}}, {'zip': '030000', 'city': 'Taiyuan', 'state': 'Shanxi', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Shanxi Provincial Cancer Hospital', 'geoPoint': {'lat': 37.86944, 'lon': 112.56028}}, {'zip': '710061', 'city': 'Xi’an', 'state': 'Shanxi', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': "The First Affiliated Hospital of Xi'An Jiaotong University", 'geoPoint': {'lat': 35.99785, 'lon': 113.52486}}, {'zip': '610000', 'city': 'Chengdu', 'state': 'Sichuan', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Sichuan Cancer Hospital', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'zip': 'Mianyang', 'city': 'Mianyang', 'state': 'Sichuan', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'ji feng', 'role': 'CONTACT', 'email': 'fengji@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Mianyang Central Hospital', 'geoPoint': {'lat': 31.46784, 'lon': 104.68168}}, {'zip': '300181', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Tianjin Medical University Cancer Institute & Hospital', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}, {'zip': '650000', 'city': 'Kunming', 'state': 'Yunnan', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Yunnan Cancer Hospital', 'geoPoint': {'lat': 25.03889, 'lon': 102.71833}}, {'zip': '310000', 'city': 'Hangzhou', 'state': 'Zhejiang', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'The Second Affiliated Hospital Zhejiang University School of Medicine', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '310003', 'city': 'Hangzhou', 'state': 'Zhejiang', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'The First Affiliated Hospital Zhejiang University School of Medicine', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '310005', 'city': 'Hangzhou', 'state': 'Zhejiang', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'Zhejiang Cancer Hospital', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '325015', 'city': 'Wenzhou', 'state': 'Zhejiang', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '02583378099'}], 'facility': 'The First Affiliated Hospital of Wenzhou Medical University', 'geoPoint': {'lat': 27.99942, 'lon': 120.66682}}], 'centralContacts': [{'name': 'xiangyu ma', 'role': 'CONTACT', 'email': 'maxy@leadsbiolabs.com', 'phone': '025-83378099-848'}], 'overallOfficials': [{'name': 'lin Shen', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Peking University Cancer Hospital & Institute'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Nanjing Leads Biolabs Co.,Ltd', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}